Unimed Sdn. BHD Pharmaceutical Import Profile — Malaysia (DGFT 2022–2026)

Name: Unimed Sdn. BHD Pharmaceutical Import Records from India — 3 Products, $3.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Unimed Sdn. BHD — Pharmaceutical Importer Profile (2026) | 3 Products, $3.1M Trade | TransData Nexus

Unimed Sdn. BHD

Pharmaceutical Importer · Malaysia · Vitamins & Supplements Focus · $3.1M Total Trade · DGFT Verified

Unimed Sdn. BHD is a pharmaceutical importer based in Malaysia with a total trade value of $3.1M across 3 products in 2 therapeutic categories. Based on 65 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Unimed Sdn. BHD sources from 4 verified Indian suppliers, with J B Chemicals And Pharmaceuticals Limited accounting for 74.2% of imports.

Unimed Sdn. BHD — Import Portfolio & Supplier Network

Unimed Sdn. BHD import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Unimed Sdn. BHD?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
J B Chemicals And Pharmaceuticals Limited	$2.4M	143	74.2%
Troikaa Pharmaceuticals Limited	$745.3K	31	23.5%
Zydus Lifesciences Limited

What Formulations Does Unimed Sdn. BHD Import?

Formulation	Value	Ships
Myonit insta nitroglycerin sublingual	$139.2K	3
Dicloran tabs 50 MG 10x 10 x 10 mal	$106.6K	6
Ifimol tabs 500MG 100x10's mal	$98.3K	3
Ifimol tabs 500MG 100x10 s mal	$98.1K	3
Metronidazole tablets 400MG. (sr no 2) mgl tabs 400 mg1x10x (10 x 10) mal exp Pack size : 1x10x(10x10)	$90.2K	2
Pamidol 300 50ML mal exp - kkm tender -(Pack size: 50ML) - pamidol 300 (iopamidol injection USP 300MG. iodine/ML	$89.9K	2
Ifimol tabs 500MG 100x10's mal exp	$89.4K	2
Cardiolek INJ 320 MG 100 ML mal exp - (Pack size: 100ML) cardiolek-320 (lodixanol injection USP 320 MG.i/ML)	$63.1K	2
Ifimol tabs 500MG 100x10's mal exp - (Pack size : 100x10's) ifimol 500 (paracetamol tablets BP 500 MG)	$61.9K	2
Metronidazole tablets 400MG. (sr no 2) mgl tabs 400 mg1x10x (10 x 10) mal exp -Pack size : 1x10x(10x10)	$50.0K	1
Pharmaceuticals formulations - myonit insta nitroglycerin sublingual tablets usp0.5 MG (details as per inv & pkg	$50.0K	1
Pharmaceuticals formulations-antiplatt clopidogrel tablet USP 75MG	$50.0K	1
Pharmaceuticals formulations myonit insta nitroglycerin sublingual tablets usp0.5MG 10x5x30t shelf life: 36	$50.0K	1
Pharmaceuticals formulations antiplattclopidogrel tablet USP 75MG 3x10t shelflife: 36	$50.0K	1
Zyrotram, tramadol hcl BP 50 MG/ML-1ML ampoules (4,83,190 ampoules of total active ingredient 24.16 kgs) tramadol	$50.0K	1

Unimed Sdn. BHD imports 126 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Zinc	Vitamins & Supplements	$2.0M	41	2.6%	9
2	Bisoprolol	Cardiovascular	$577.7K	15	0.7%	18
3	Nitroglycerin	Cardiovascular	$450.0K	9	3.1%	2

Unimed Sdn. BHD imports 3 pharmaceutical products across 2 categories into Malaysia totaling $3.1M.

Unimed Sdn. BHD — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Unimed Sdn. Bhd., established in 1981, is a prominent pharmaceutical company headquartered in Kuala Lumpur, Malaysia. With over four decades of experience, Unimed specializes in importing, marketing, and distributing a diverse range of healthcare products, including generic pharmaceutical formulations, nutraceuticals, medical devices, and herbal supplements. The company operates with a dedicated workforce of approximately 250 employees, encompassing a committed sales team that plays a pivotal role in advancing Unimed's mission and vision. (unimed.com.my)

Unimed's operations extend across Peninsular Malaysia, East Malaysia, Singapore, and Brunei, reflecting its significant presence in the Southeast Asian region. The company's strategic expansion beyond ASEAN includes markets such as Hong Kong, Yemen, and Iraq, underscoring its global outreach. In 2008, Unimed expanded its manufacturing capabilities by acquiring KCK Pharmaceutical Industries Sdn. Bhd. in Penang, Malaysia. This facility, staffed by approximately 300 employees, produces a variety of products, including oral liquids, solids, creams, and ointments, primarily serving government hospitals and general practitioner clinics in Malaysia. (unimed.com.my)

2Distribution Network

Unimed Sdn. Bhd. has developed a robust distribution network to ensure efficient delivery of its products across Malaysia and beyond. The company's headquarters in Kuala Lumpur serve as the central hub for its operations. To enhance logistics and distribution management, Unimed has expanded its warehouse facilities, facilitating prompt and reliable service to its customers. (unimedonline.com.my)

In addition to its domestic operations, Unimed has initiated logistics and distribution hubs in Sarawak, Sabah, and Kedah, aiming to create a sustainable supply chain management system. These hubs are expected to bolster the company's distribution capabilities, ensuring timely and efficient delivery of products to various regions. (unimed.com.my)

3Industry Role

Unimed Sdn. Bhd. plays a multifaceted role in Malaysia's pharmaceutical supply chain. As a primary wholesaler and distributor, the company imports a wide array of pharmaceutical products, including generic finished formulations, medical devices, and nutraceuticals. Its operations encompass the entire supply chain, from sourcing and importing products to marketing and distributing them to various healthcare providers and institutions. This comprehensive approach positions Unimed as a key player in ensuring the availability of quality healthcare products in Malaysia. (unimed.com.my)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Unimed Sdn. BHD

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Unimed Sdn. Bhd. demonstrates a high degree of sourcing concentration, with a total import value from India amounting to $3.1 million USD across 65 shipments. The company's portfolio is heavily concentrated, with the top five products accounting for 100% of the total import value. This concentration indicates a strategic focus on specific products, potentially leveraging favorable pricing or established supplier relationships.

The primary supplier, J B Chemicals and Pharmaceuticals Limited, accounts for 74.2% of the total import value, suggesting a strong and stable relationship. Secondary suppliers, such as Troikaa Pharmaceuticals Limited and Zydus Lifesciences Limited, contribute 23.5% and 1.8%, respectively. The limited number of suppliers and the dominance of a single supplier may expose Unimed to risks related to supply chain disruptions or changes in supplier dynamics. However, this concentration could also reflect strategic partnerships and streamlined procurement processes.

2Supply Chain Resilience

Unimed Sdn. Bhd.'s supply chain resilience is influenced by its concentrated sourcing strategy. The reliance on a limited number of suppliers, particularly J B Chemicals and Pharmaceuticals Limited, may pose risks in the event of supply chain disruptions, regulatory changes, or shifts in supplier priorities. The company's focus on a narrow range of products, with the top five accounting for the entire import value, further underscores this concentration.

Importing Pharmaceuticals into Malaysia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Malaysia

1Regulatory Authority & Framework

In Malaysia, the primary regulatory authority overseeing pharmaceutical imports is the National Pharmaceutical Regulatory Agency (NPRA), operating under the Ministry of Health. The NPRA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products available in the Malaysian market. Key legislation governing pharmaceutical imports includes the Sale of Drugs Act 1952 and the Control of Drugs and Cosmetics Regulations 1984, which provide the legal framework for the registration, importation, and distribution of pharmaceutical products.

For Indian generics to be marketed in Malaysia, they must undergo a registration process with the NPRA. This process involves submitting comprehensive documentation, including product dossiers, clinical data, and evidence of Good Manufacturing Practice (GMP) compliance. The NPRA evaluates these submissions to ensure that imported generics meet the required standards for safety, efficacy, and quality.

2Import Licensing & GMP

Import licensing requirements in Malaysia stipulate that pharmaceutical products must be registered with the NPRA before they can be imported and marketed. Manufacturers and importers must obtain a valid import license, which is contingent upon the registration status of the product. Additionally, the NPRA recognizes GMP certificates from internationally accredited bodies, such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition facilitates the acceptance of foreign manufacturing standards, provided they align with Malaysia's regulatory requirements.

Unimed Sdn. BHD — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Unimed Sdn. Bhd.'s product strategy focuses on importing niche pharmaceutical products and locally manufacturing generics for regional and international markets. The company's emphasis on niche generics and nutritional supplements aligns with its mission to provide cost-effective healthcare solutions to its stakeholders. By focusing on these specific therapeutic areas, Unimed aims to meet the diverse healthcare needs of the Malaysian population while maintaining a competitive edge in the market. (unimed.com.my)

2Sourcing Profile

Unimed Sdn. Bhd. primarily sources generic pharmaceutical products from India, leveraging the country's established manufacturing capabilities and cost advantages. The company's sourcing strategy involves importing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. This approach allows Unimed to offer a diverse product portfolio while ensuring compliance with Malaysia's regulatory standards.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Unimed Sdn. BHD

What products does Unimed Sdn. BHD import from India?

Unimed Sdn. BHD imports 3 pharmaceutical products across 2 categories. Top imports: Zinc ($2.0M), Bisoprolol ($577.7K), Nitroglycerin ($450.0K).

Who supplies pharmaceuticals to Unimed Sdn. BHD from India?

Unimed Sdn. BHD sources from 4 verified Indian suppliers. The primary supplier is J B Chemicals And Pharmaceuticals Limited (74.2% of imports, $2.4M).

What is Unimed Sdn. BHD's total pharmaceutical import value?

Unimed Sdn. BHD's total pharmaceutical import value from India is $3.1M, based on 65 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Unimed Sdn. BHD focus on?

Unimed Sdn. BHD imports across 2 categories. The largest: Vitamins & Supplements (66.6%), Cardiovascular (33.4%).

Get Full Unimed Sdn. BHD Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.